Use of Quinolones in the Immunocompromised Host

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 1991 Apr 1

PMID 1864298

Citations 2

Authors

A G Maiche

Affiliations

Soon will be listed here.

Abstract

Immune deficiency generally leads to infections. Cancer chemotherapy, medical interventions and various investigational procedures are important factors in the development of infection. In recent decades, there has been a major change in most cancer centers in the etiology of bacterial infections occurring in the immunocompromised host, most infections now being caused by gram-positive organisms. This might be partly due to prophylactic use of agents effective against gram-negative bacteria. The quinolones are now widely used in the treatment of serious infections of the immunocompromised patient. Prophylaxis with quinolones is also practised in cancer centers.

Citing Articles

In vitro antibiotic susceptibility testing of clinical isolates of Mycoplasma penetrans from patients with AIDS.

Hayes M, Foo H, Timenetsky J, Lo S Antimicrob Agents Chemother. 1995; 39(6):1386-7.

PMID: 7574538 PMC: 162749. DOI: 10.1128/AAC.39.6.1386.

Quinolone antibacterials. An update of their pharmacology and therapeutic use.

von Rosenstiel N, Adam D Drugs. 1994; 47(6):872-901.

PMID: 7521829 DOI: 10.2165/00003495-199447060-00003.

References

Karp J, Dick J, Merz W . Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient. Eur J Cancer Clin Oncol. 1988; 24 Suppl 1:S5-13. View

Bow E, Rayner E, Louie T . Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. Am J Med. 1988; 84(5):847-54. DOI: 10.1016/0002-9343(88)90062-9. View

Calandra T, Klastersky J, Gaya H, Glauser M, Meunier F, Zinner S . Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 1987; 317(27):1692-8. DOI: 10.1056/NEJM198712313172703. View

Rozenberg-Arska M, Dekker A, Verhoef J . Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J Infect Dis. 1985; 152(1):104-7. DOI: 10.1093/infdis/152.1.104. View

Winston D, Ho W, Champlin R, Karp J, Bartlett J, Finley R . Norfloxacin for prevention of bacterial infections in granulocytopenic patients. Am J Med. 1987; 82(6B):40-6. DOI: 10.1016/0002-9343(87)90617-6. View

Wade J, Schimpff S, Newman K, Wiernik P . Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med. 1982; 97(4):503-8. DOI: 10.7326/0003-4819-97-4-503. View

Schimpff S . Infection prevention during profound granulocytopenia. New approaches to alimentary canal microbial suppression. Ann Intern Med. 1980; 93(2):358-61. DOI: 10.7326/0003-4819-93-2-358. View

Hartlapp J . Antimicrobial prophylaxis in immunocompromised patients. Drugs. 1987; 34 Suppl 1:131-3. DOI: 10.2165/00003495-198700341-00028. View

Sleijfer D, Mulder N, de Vries-Hospers H, Fidler V, NIEWEG H, Van Der Waaij D . Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer (1965). 1980; 16(6):859-69. DOI: 10.1016/0014-2964(80)90140-1. View

10.

Shah P . Use of quinolones for the treatment of patients with bacteremia. Rev Infect Dis. 1989; 11 Suppl 5:S1156-9. DOI: 10.1093/clinids/11.supplement_5.s1156. View

11.

Rotstein S, Blomgren H, Baral E, Lax I, Israelsson A, Nilsson B . Incidence of infectious symptoms after radiation therapy for breast cancer. Long-term effects. Acta Oncol. 1987; 26(3):197-201. DOI: 10.3109/02841868709091431. View

12.

ABRAHAMSEN A, Borge L, Holte H . Infection after splenectomy for Hodgkin's disease. Acta Oncol. 1990; 29(2):167-70. DOI: 10.3109/02841869009126539. View

13.

Dennig D, Fulle H, Hellriegel K . Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin. Onkologie. 1987; 10(1):57-8. DOI: 10.1159/000216371. View

14.

Neu H . Synergy of fluoroquinolones with other antimicrobial agents. Rev Infect Dis. 1989; 11 Suppl 5:S1025-35. DOI: 10.1093/clinids/11.supplement_5.s1025. View

15.

Ziegler E, McCutchan J, Fierer J, Glauser M, Sadoff J, Douglas H . Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982; 307(20):1225-30. DOI: 10.1056/NEJM198211113072001. View

16.

Maschmeyer G, Haralambie E, Gaus W, Kern W, Dekker A, de Vries-Hospers H . Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia. Infection. 1988; 16(2):98-104. DOI: 10.1007/BF01644312. View

17.

Smith G, Leyland M, Farrell I, Geddes A . A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients. J Antimicrob Chemother. 1988; 21(5):647-55. DOI: 10.1093/jac/21.5.647. View

18.

Klastersky J . Empiric antimicrobial therapy for febrile granulocytopenic cancer patients. Lessons from four EORTC trials. Acta Oncol. 1988; 27(5):497-502. DOI: 10.3109/02841868809093577. View

19.

Schimpff S, Satterlee W, YOUNG V, Serpick A . Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971; 284(19):1061-5. DOI: 10.1056/NEJM197105132841904. View

20.

Pizzo P, Hathorn J, Hiemenz J, Browne M, Commers J, Cotton D . A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986; 315(9):552-8. DOI: 10.1056/NEJM198608283150905. View